aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
aTyr Pharma, Inc.NASDAQ: ATYR
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 10.1% from a year ago
Common stock stood at $98K at the end of Q1 FY2026, up 10.1% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +50.1% a year.
Context
- Common stock amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +10.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 98K USD
- Year-over-year change
- +16.7%
- 4-year CAGR
- +36.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 98K | +16.7% |
| FY2024 | 2024-12-31 | 84K | +33.3% |
| FY2023 | 2023-12-31 | 63K | +117.2% |
| FY2022 | 2022-12-31 | 29K | +3.6% |
| FY2021 | 2021-12-31 | 28K | — |
Common Stock vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +10.1% is the 5th highest of 8, against a peer median of +22.6%.
- Common stock amounts to 0.1% of total assets for ATYR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$138.37M CAD | +1.5% | +6.0% | 597.3% |
| Mar 2026 | $135K USD | +154.7% | +9.6% | 0.1% | |
| Mar 2026 | $104.89K USD | +216.0% | +34.6% | 0.0% | |
| Mar 2026 | $98K USD | +10.1% | +50.1% | 0.1% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $38K USD | +22.6% | +12.1% | 0.0% |
| Mar 2026 | $25K USD | -79.2% | +13.6% | 0.0% | |
| Mar 2026 | $6K USD | +200.0% | — | 0.0% | |
| Mar 2026 | $1K USD | +0.0% | +0.0% | 0.0% | |
| Peer median (excluding ATYR) | — | +22.6% | +10.9% | 0.0% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.34M | 9.98M | 22.54M | 11.06M | 10.74M |
| Short-term Investments | 105.58M | 56.17M | 75.62M | 61.07M | 67.94M |
| Net Receivables | 435K | 11.78M | 2.44M | 1.74M | 873K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 113.57M | 80.87M | 102.99M | 81.95M | 80.24M |
| Property, Plant & Equipment (Net) | 1.81M | 11.56M | 14.05M | 11.86M | 10.38M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.24M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 158K | 3.36M | 3.62M | 3.02M | 1.31M |
| Total Non-current Assets | 1.97M | 14.92M | 17.66M | 14.88M | 13.93M |
| Total Assets | 115.54M | 95.79M | 120.65M | 96.83M | 94.16M |
| Account Payables | 1.03M | 3.11M | 3.53M | 4.32M | 3.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.47M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 6.81M |
| Total Current Liabilities | 6.01M | 13.86M | 16.42M | 14.97M | 15.15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.16M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 398K | 10.64M | 13.77M | 12.03M | 11.73M |
| Total Liabilities | 6.41M | 24.5M | 30.18M | 27M | 26.88M |
| Common Stock | 28K | 29K | 63K | 84K | 98K |
| Retained Earnings | (372.3M) | (417.63M) | (468.02M) | (532.05M) | (606.16M) |
| Accumulated OCI | (263K) | (433K) | (74K) | (40K) | (8K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (175K) | (180K) | (188K) | (187K) | (192K) |
| Total Equity | 109.13M | 71.28M | 90.47M | 69.83M | 67.29M |
| Total Debt | 1.38M | 11.53M | 15.1M | 13.28M | 12.03M |
| Net Debt | (958K) | 1.55M | (7.45M) | 2.23M | 1.29M |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.